Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 424,900 shares, a decrease of 20.5% from the October 31st total of 534,200 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 1.0% of the shares of the company are sold short.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Thoroughbred Financial Services LLC acquired a new stake in Mustang Bio during the second quarter worth about $25,000. Koss Olinger Consulting LLC bought a new stake in shares of Mustang Bio in the 2nd quarter worth approximately $47,000. Finally, Virtu Financial LLC acquired a new stake in shares of Mustang Bio during the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 9.95% of the company’s stock.

Mustang Bio Stock Up 5.3 %

Shares of MBIO stock traded up $0.01 during trading hours on Friday, reaching $0.20. 404,783 shares of the company’s stock were exchanged, compared to its average volume of 8,779,562. Mustang Bio has a fifty-two week low of $0.13 and a fifty-two week high of $1.66. The stock has a market capitalization of $9.56 million, a P/E ratio of -0.13 and a beta of 1.92. The business has a fifty day moving average price of $0.24 and a 200-day moving average price of $0.30.

Mustang Bio (NASDAQ:MBIO) last released its earnings results on Friday, November 8th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.09. As a group, research analysts expect that Mustang Bio will post -0.7 EPS for the current fiscal year.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.